title: Gender differences in macroprolactinomas: a single centre experience.
abstract: Macroprolactinomas are the most common functional pituitary tumours. Hypotheses proposed to explain predominance of large tumours in males are: i) diagnostic delay, as hyperprolactinaemia remains under recognised in males and ii) gender-specific difference in tumour proliferation indices. Our study objectives are to compare gender differences in clinical, biochemical, radiological features, management outcomes and cabergoline responsiveness in macroprolactinomas. Drug resistance was defined as failure to achieve prolactin normalisation and >50% reduction in tumour volume with cabergoline (3.5 mg/week dose for minimum 6 months duration). The baseline characteristics of 100 patients (56 females and 44 males) with macroprolactinoma were analysed. Drug responsiveness was analysed in 88 treatment naive patients, excluding 12 post-primary trans-sphenoidal surgery cases. We found that females (30.29±10.39 years) presented at younger mean age than males (35.23±9.91 years) (P<0.01). The most common presenting symptom was hypogonadism (oligo-amenorrhoea/infertility) in females (96.15%) and symptoms of mass effect (headache and visual field defects) in males (93.18%). Baseline mean prolactin levels were significantly lower in females (3094.36±6863.01 ng/ml) than males (7927.07±16 748.1 ng/ml) (P<0.001). Maximal tumour dimension in females (2.49±1.48 cm) was smaller than males (3.93±1.53 cm) (P<0.001). In 88 treatment naïve patients, 27.77% females and 35.29% males had resistant tumours (P=0.48). On subgrouping as per maximum tumour dimension (1.1-2 cm, 2.1-4 cm and >4 cm), gender difference in response rate was insignificant. In conclusion, macroprolactinomas are equally prevalent in both sexes. Macroprolactinomas in males predominantly present with symptoms of mass effects, as against females who present with symptoms of hypogonadism. Males harbor larger tumours but are equally cabergoline responsive as those in females.
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India shrutigkhare@yahoo.co.in.
authors.forename: Shruti
authors.initials: S
authors.lastname: Khare
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Anurag R
authors.initials: AR
authors.lastname: Lila
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Hiren
authors.initials: H
authors.lastname: Patt
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Chaitanya
authors.initials: C
authors.lastname: Yerawar
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Manjunath
authors.initials: M
authors.lastname: Goroshi
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Tushar
authors.initials: T
authors.lastname: Bandgar
authors.affiliation: Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.
authors.forename: Nalini S
authors.initials: NS
authors.lastname: Shah
keywords: cabergoline resistance; gender differences; macroprolactinoma; responsiveness